Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis
This study provides Class IV evidence that in persons with RMS with NEDA-3 in the 12 months following RTX, extending the dosing interval to 12 months did not increase the risk of disease activity compared with continuing q6mo dosing.
Authors
- Ferràn Torres (ORCID: https://orcid.org/0000-0002-7355-7913)
- Brandon Beaber
- Sonu M. Brara
- Stanley Xu (ORCID: https://orcid.org/0000-0002-4750-7672)
- Jessica Smith (ORCID: https://orcid.org/0000-0001-6585-323X)
- Annette Langer-Gould
- Bonnie H. Li
- A. Scott Nielsen
- Samira Amirova
Institutions
- Kaiser Permanente (US)
- Los Angeles Medical Center (US)
- Kaiser Permanente Fontana Medical Center (US)
- Colorado Permanente Medical Group (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1212/wnl.0000000000214473
- Citations
- 2
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.61